ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | 0.55 |
| FCF Yield | -642.48% | -993.80% | -10.49% | -3.17% |
| EV / EBITDA | 0.00 | 0.02 | -0.59 | -23.32 |
| Quality | ||||
| ROIC | -97,461.45% | -110.29% | -11.90% | 230.08% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.09 | 0.35 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 13.31% | -483.47% | 70.56% | 0.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.03 | 0.40 | -1.22 |
| Interest Coverage | -33,858.18 | 0.00 | -32.36 | -9.38 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -491,576.87 | -295,916.13 | -211,476.96 | -70,195.82 |